Riluzole CAS: 1744-22-5

CAS NO: 1744-22-5
Riluzole
Chemical Name: Riluzole
Molecular Formula: C8H5F3N2OS
Formula Weight: 234.2
CAS No.: 1744-22-5
Description Review
Description

Riluzole is a neuroprotective drug used primarily in the treatment of amyotrophic lateral sclerosis (ALS). In this article, we will delve into the chemical properties of riluzole, its health benefits, potential effects, mechanism of action, possible side effects, and dosing information.

Chemical Properties

The chemical name of riluzole is 2-amino-6-(trifluoromethoxy)benzothiazole. Its molecular formula is C8H5F3N2OS and formula weight is 234.2 g/mol. The CAS number of riluzole is 1744-22-5.

Top Ten Keywords and Synonyms

  1. Neuroprotective agent
  2. Riluzole
  3. ALS treatment
  4. Glutamate toxicity
  5. Motor neuron disease therapy
  6. Anxiety disorders
  7. Antidepressant medication
  8. Excitotoxicity
  9. Mood stabilizer
  10. Bipolar disorder

Synonyms:

  1. Riluzole
  2. 2-Amino-6-(trifluoromethoxy)benzothiazole

Health Benefits

Riluzole has shown potential benefits in treating amyotrophic lateral sclerosis (ALS) by slowing down the progression of the disease and improving patient survival rates. It may also have applications in treating other neurological conditions such as anxiety disorders, depression, mood disorders, and bipolar disorder.

Potential Effects

Riluzole primarily acts as an inhibitor of glutamate release and reuptake, a neurotransmitter that plays a critical role in the regulation of neuronal function. By inhibiting glutamate release and reuptake, riluzole can reduce excitotoxicity, which ultimately slows down the progression of diseases such as ALS. Additionally, it may have applications as an antidepressant and mood stabilizer by regulating glutamate levels in the brain.

Product Mechanism

Glutamate is a neurotransmitter that plays a critical role in regulating neuronal function. However, excessive glutamate release and reuptake can lead to excitotoxicity, a process that damages neurons and contributes to various neurological disorders such as ALS. Riluzole selectively inhibits glutamate release and reuptake, thereby reducing excitotoxicity and slowing down the progression of various neurological disorders.

Safety

Riluzole has demonstrated a good safety profile in clinical studies. However, it may interact with other medications and cause adverse reactions in some patients. Patients with liver disease or kidney disease should use caution when taking riluzole, and dosage adjustments may be necessary.

Side Effects

Common side effects of riluzole include nausea, dizziness, and fatigue. Rare but serious side effects include liver dysfunction and allergic reactions. Patients should seek medical attention immediately if they experience any serious side effects or symptoms.

Dosing Information

The recommended dose of riluzole for the treatment of ALS is 50 mg twice daily. The optimal dose and duration of treatment for other neurological disorders are unknown, and further research is needed to establish safe and effective dosing regimens.

Conclusion

Riluzole is a promising neuroprotective agent with potential therapeutic applications in treating various neurological disorders such as ALS, anxiety disorders, depression, mood disorders, and bipolar disorder. Its mechanism of action involves inhibiting glutamate release and reuptake, thereby reducing excitotoxicity and slowing down the progression of various neurological disorders. While it has demonstrated a good safety profile in clinical studies, more research is needed to determine its long-term safety and potential side effects in humans. Nonetheless, riluzole has great potential as a novel therapeutic agent in the treatment of various neurological disorders.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code